Back to Insights

EIT Pathogena Launches SARS-CoV-2 Genomic Analysis Pipeline

Press Release
EIT Pathogena new SARS-CoV-2 genomic analysis pipeline unveiled today at the Festival of Genomics and Biodata in LondonJanuary 30, 2025 — Editorial Team
[London, 30 January 2025] – EIT Pathogena is proud to announce the launch of its SARS-CoV-2 genomic analysis pipeline, designed to empower researchers, healthcare professionals, and public health agencies in their ongoing efforts to monitor and combat the virus. It follows the release of the Mycobacterium pipeline and represents a leap forward in infectious disease research, offering a high-throughput, cloud-based solution for fast and accurate genomic analysis.
The new pipeline was launched today at the Festival of Genomics and Biodata. As part of the launch, Dr. Emma Stanton, EIT Pathogena CEO, delivered a talk titled "Going Viral: Revolutionising Infectious Diseases Through Genomics".

The launch builds on EIT Pathogena’s commitment to innovation, accessibility, and collaboration in pathogen genomics. By leveraging advanced analytics and automated workflows, the new platform enables users to analyse large-scale SARS-CoV-2 genomic data efficiently, providing critical insights into virus evolution, transmission dynamics, and emerging variants.

Key Features of the Platform:

  • Cloud-Based & Scalable: Designed to handle high-throughput genomic data, ensuring fast analysis and safe storage.
  • User-Friendly Interface: Allows for intuitive navigation and easy data interpretation.
  • Free Self-Sign-Up: Users can easily access the platform and begin analysis without barriers.

“We are excited to introduce this tool to the global research community,” said Dr. Emma Stanton, CEO at EIT Pathogena. “The COVID-19 pandemic has underscored the need for real-time genomic surveillance, and our platform provides an accessible, high-quality solution to support ongoing monitoring and preparedness efforts.”

EIT Pathogena has partnered with leading institutions and global health organisations to ensure the platform aligns with the needs of epidemiologists and genomic researchers. This launch is part of EIT Pathogena’s broader mission to revolutionise genomic analysis in infectious diseases, supporting researchers and public health officials with cutting-edge technology that drives real-world impact.

For more information about the SARS-CoV-2 pipeline or to sign up, visit here.

About EIT Pathogena

EIT Pathogena is dedicated to reducing the millions of lives lost through the inappropriate treatment of infectious diseases and preventing the escalation from local outbreaks to pandemics. By developing a global, "Always-On" pathogen detection and monitoring system, we aim to revolutionise infectious disease prevention and treatment. Our cloud-based, automated bioinformatics platform provides rapid, accurate genomic analysis, empowering researchers and public health professionals worldwide. Through authentic collaboration and cutting-edge technology, we strive to create a more resilient global health system.

Media Contact: Alessia Gasco Marketing Manager EIT Pathogena agasco@eit.org